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CC BY-NC-ND license (http://creativeAbstract Neutral lipid storage disease with myopathy (NLSDM) is a rare autosomal recessive
disorder, due to an enzymatic error of lipid metabolism. Patients present always with skeletal
muscle myopathy and variable cardiac and hepatic involvement. NLSDM is caused by mutations
in the PNPLA2 gene, which encodes the adipose triglyceride lipase (ATGL). Here we report the
molecular characterization and clinical findings of two NLSDM siblings carrying the novel
c.187þ1G > C homozygous PNPLA2 mutation, localized in the splice site of intron 2. Molecular
analyses revealed that neither aberrant PNPLA2 mRNA isoforms, nor ATGL mutated protein
were detectable in patient’s cells.
Clinically, both patients presented early onset muscle weakness, in particular of proximal
upper limb muscles. In almost 15 years, muscle damage affected also distal upper limbs.
This is a NLSDM family, displaying a severe PNPLA2 mutation in two siblings with clinical pre-
sentation characterized by an early onset, but a slowly evolution of severe myopathy.
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Lipid storage myopathies (LSMs) are a group of metabolic
disorders caused by different errors of fats metabolism.1
Impairment of ability to metabolize fats induces an
abnormal lipid storage in muscle fiber, as well as in other
tissues.
Loss or decrease of adipose triglyceride lipase (ATGL)
function is the biochemical defect associated with the
onset of a particular LSM, called neutral lipid storage dis-
ease with myopathy (NLSDM; MIM 610717).2 ATGL is a lipid
droplet-associated enzyme which mobilizes the first fatty
acid from triacylglycerols (TAGs), stored within lipid drop-
lets (LDs).3 ATGL protein is composed of 504 amino acids
and shows two functional regions: a patatin domain (amino
acids I10-L178), containing the catalytic dyad (amino acids
S47 and D166) and also three LC3-interacting region (LIR)
motifs (amino acids C15eV20; P86eV91; S145eV150), and a
hydrophobic domain (amino acids P315eP360), involved in
LD binding.4,5
Until now, forty different PNPLA2 mutations have been
identified.2,6e15 The majority of them determine either no
protein production or the synthesis of truncated proteins.
These mutants show loss of function or a severe decrease of
enzymatic activity. The remaining variants are missense
mutations, which usually maintain a residual lipolytic
activity.11,16,17
NLSDM is an autosomal recessive inborn error of neutral
lipid metabolism, reported in 56 subjects worldwide.2,6e20
In this LSM, TAGs are accumulated in cytoplasmic LDs of
most tissues, including muscles, heart, liver and peripheral
blood. Histological and electron microscopy findings reveal
a markedly increase in the number and dimension of LDs
located in the muscle fibers, particularly in type I fi-
bers.13,14,17,19 The abnormal storage of neutral lipid pri-
marily determines a progressive skeletal muscle myopathy
which involves both proximal and distal muscles. In ad-
vances cases, muscular atrophy can also be observed. Other
clinical symptoms are cardiomyopathy, hepatomegaly,
diabetes, chronic pancreatitis and short stature.
In this study we clinically and genetically characterized
two siblings affected by NLSDM. In these patients a novel
splice site mutation of PNPLA2 gene was identified. This
mutation completely abolishes PNPLA2 mRNA and ATGL
protein production, causing an early onset of severe pro-
gressive skeletal muscle myopathy but with slow evolution.
Materials and methods
An Italian NLSDM patient was recruited. This study was
conducted in full accordance with the World Medical As-
sociation Declaration of Helsinki (version 2008). Informed
consent for genetic analysis was obtained from patient and
healthy subjects.
Muscle histopathology
Routine standard histological techniques, including hae-
matoxylin & eosin (H&E), and Oil-Red-O (ORO), were
applied to transverse sections (8 mm thick) of the quadri-
ceps muscle biopsy.For electron microscopy, a small fragment of muscle
tissue was fixed in 4% glutaraldehyde in phosphate buffer,
postfixed in osmium tetroxide, dehydrated, and embedded
in epon resin. Thin sections were examined with an elec-
tron microscope (FEI Tecnai G2).
Myoblasts cell culture
NLSDM and control myoblasts were obtained from muscle
biopsies and cultured in DMEM supplemented with 20% FBS,
1% penicillinstreptomycin, 2 mM L-glutamine, 10 mg/ml
insulin (Sigma-Aldrich), 2.5 ng/ml basic fibroblast growth
factor (Gibco), and 10 ng/ml epidermal growth factor
(Gibco).
Myoblasts were seeded on coverslips, stained with Nile
Red (NR) and DAPI, and observed with a Leica MB5000B
microscope. Fluorescence images were captured using a
Leica DFC480 R2 digital camera and a Leica Application
Suite (LAS) software.
Genomic DNA investigation
Peripheral blood samples were obtained from male patient
and healthy subjects. Genomic DNA was extracted using
Puregene DNA Isolation kit (Qiagen, Venlo, Netherlands).
Genetic analysis of PNPLA2 exons sequence and their
flanking regions was performed as previously reported
(Tavian et al, 2012). All PCR products were purified using
NucleoSpin Extract II (Macherey-Nagel, Germany) and
sequenced on 3730 DNA analyser by the BigDyew Termi-
nator V1.1 Cycle sequencing kit (Applied Biosystems, Foster
City, CA, USA).
RT-PCR analysis of PNPLA2 gene expression in
myoblasts
RNA was isolated from myoblasts using TRIzol (Invitrogen,
Carslbad, CA, USA), treated with DNase I (ThermoFosher
Scientific, Waltham, MA, USA) and converted to cDNA as
previously described (Tavian et al, 2012). 50 ng of cDNA
were amplified using the following primers: ATGL-1F
(GCGGCCCCAGTCAGACGCAG) and ATGL-2R (CTCGCGGGG
AAACATCGCGG); ATGL-2F (TTCTTCGCCTCCGCCAGCGG) and
ATGL-3R (CTCGCGGGGAAACATCGCGG); ATGL-3F (TCTAAA-
GAGGCCCGGAAGCG) and ATGL-7R (GTAATCCTCCGCTT
GGGCGC); ATGL-7F (CTGAACCGGCCCAACCCCTT) and ATGL-
10R (GGTCCGCGGGGGCGGGAG). GAPDH expression was
used as the internal control.21
Results
Case presentation
The proband presented around the age of 30 years with
proximal upper limb muscle weakness, followed by
involvement of lower limbs. His previous medical history
had been unremarkable. The disease slowly progressed
over the years and the patient was wheelchair-bound at the
age of 46 years. At the same age, distal weakness of upper
limbs was noticed. He has never reported bulbar or ocular
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age of 35 years showed a myopathic pattern. At the age of
48 years a heart echo scan showed apical and lateral
hypokinesis. Creatine kinase ranged between 1126 and
1574 U/L (normal value < 190 U/L). The patient was first
admitted in our outpatient clinic at the age of 49 years.
Neurological examination showed no antigravitary move-
ments of proximal and distal upper limb muscles, slightly
worse on wrist and finger extensors than in flexors, foot
dorsal flexion and, limited to the right side, thigh and knee
extension. In addition, neck extensor muscles were
moderately (MRC Z 3) weak and mild (MRC Z 4) weakness
of thigh flexion on the right and knee extension on the left
side was observed. The patient was able to get up from the
wheelchair with the help of upper limbs and able to stand
with support, but not able to walk. Cranial nerves were
normal. Tendon retractions or scapular winging were ab-
sent. Forced vital capacity was reduced to the 60% of
normal value and the patient had no indication for non-
invasive ventilation (NIV). A muscle biopsy, taken at age 50,
revealed vacuolated fibers on H&E (Fig. 1a) and lipid
droplets accumulation on O.R.O staining (Fig. 1b). More-
over, electron microscopy showed numerous LDs located
between myofibrils in most fibers (Fig. 1c). Finally, myo-
blasts, stained with NR, exhibited an excessive neutral
lipids storage in the LDs (Fig. 1d). The patient was then lost
to follow-up and died at the age of around 54 years,
probably due to heart problems.
Parents were not consanguineous, but born in the same
small town. The proband had a healthy brother and a sister
displaying similar pathological features, although present-
ing earlier, at the age of 18 years. The affected sister was
wheelchair-bound since the age of 33 years, required NIV
since the age of 46 years, whereas tracheostomy for res-
piratory failure and pace-maker implantation were per-
formed at the age of 47 years. Unfortunately, she was never
investigated in our institute.
Molecular analysis
PNPLA2 gene investigation detected a novel homozygous
splice site mutation (c.187þ1G > C), which was submitted
to GenBank (accession number MK645897) (Fig. 2a). This
mutation was not found in 100 healthy controls nor was
present in dbSNP, 1000 genomes and Exome Variant Server
data banks. The variation is localized in the splice site of
intron 2 and is predicted to cause the retention of intron 2,
producing an aberrant mRNA and a truncated ATGL protein.
However, a comparative PNPLA2 RT-PCR analysis, per-
formed from myoblasts of male patient and a control sub-
ject, revealed that in NLSDM sample no PNPLA2mRNA could
be detected (Fig. 2b). Moreover, Western blotting investi-
gation showed the lack of ATGL protein production in
NLSDM cells (data not shown).
Discussion
ATGL deficiency causes defects of neutral lipids metabolism
and an excessive storage of TAGs in cytoplasmic LDs. The
impairment of TAGs hydrolysis determines NLSDM onset. In
this disorder the genotypeephenotype correlation is noteasily established. In general, the majority of patients,
carrying mutations which lead a dramatic decrease of ATGL
function, have a severe outcome. These subjects, in addi-
tion to an early onset of skeletal muscle myopathy, often
develop a cardiac dysfunction (40% of patients) with clinical
manifestations ranging from minimal symptoms to severe
conditions.6,12,13,20 On the contrary, NLSDM patients with
ATGL variations that retain a residual lipolytic activity may
show a slow progressive myopathy, without hearth
failure.16,17
In this study we report two siblings presenting early
muscle damage which slowly progressed over the years.
This clinical phenotype is related to a PNPLA2 mutation
that results in complete loss of gene expression. Usually, a
splice site mutation does not determine the lack of
mRNA.22 Sometimes, splice site mutations can activate
cryptic sites determining the creation of novel donor or
acceptor points.23 In the muscle of our patient we failed to
detect PNPLA2 mRNA. Similarly, no PNPLA2 transcript was
detected in two NLSDM Chinese patients, characterized by
a mutation in the donor site of intron 6 (IVS6 þ 2T).10 In rare
cases, it could be hypothesized that some mutations in the
splicing canonical points cause the creation of cryptic
splice sites and the production of very unstable mRNAs
which are immediately degraded. Further studies are
needed to find which mechanisms are involved in the full
lack of PNPLA2 transcript.
A different homozygous PNPLA2 mutation affecting the
same invariant nucleotide of the donor splice-site of intron
2 (c.187 þ 1G > A) has previously been described in two
Chinese families.8,24 In the first family, there were 2 sib-
lings who manifested muscle weakness since the age of 35
(female patient) and 45 (male patient). In addition, male
subject displayed dilated cardiomyopathy. In the second
family, two brothers, who developed muscle weakness in
the middle age and presented cardiac defects, were
described. Despite similar PNPLA2 mutation, in our patients
muscle weakness presented earlier than in Chinese sub-
jects, but myopathy progression was slow. Moreover, our
female patient manifested late onset of respiratory dam-
age, and only 30 years after the onset of muscle weakness,
she needed pacemaker implantation. These clinical dif-
ferences might be related to many factors: genetic modi-
fiers which can change disease development,25 epigenetic
influences, as well as different lifestyle, diet and gender.
Indeed, the analysis of NLSDM patients described
worldwide might support the hypothesis that the pheno-
type variability of this LSM might explained not only by
different PNPLA2 mutations but also to others causes.
Generally, in the presence of PNPLA2mutations with similar
effects on ATGL activity, Far East patients showed a more
severe cardiac involvement, compared to NLSDM subjects
from Italy.15 Moreover, some authors reported clinical
variability in siblings with the same PNPLA2 mutations. We
described an Italian family in which the daughter man-
ifested leg myalgia and cramps at the age of 25, while her
brother, who was an athlete, had the first symptoms (leg
cramps) at 40 years of age.11 In a Japanese family, two
affected members were identified. The female presented
at the age of 21 muscle weakness that evolved in slowly
progressive skeletal myopathy with cardiac involvement.
She died at the age of 66 for hearth failure. Her brother
Figure 1 Histochemical characterization of NLSDM male patient. Muscle biopsy cryosections, stained with haematoxylin & eosin
(a) and Oil-Red-O (b), reveal microvacuoles and abnormal storage of lipids. (c) Electron microscopy displays massive line-up of lipid
droplets without signs of mitochondrial alteration. (d) Immunofluorescent image of cultured myoblasts shows increase of lipid
droplet accumulation inside the cells. Myoblasts are stained with Nile Red and nuclei are counterstained with DAPI (blue).
Figure 2 Identification and molecular characterization of PNPLA2 mutation. (a) Electropherogram of PNPLA2 exon 2-intron 2
showing a splice-site mutation (c.187þ1G > C) in homozygous status. (b) RT-PCR analysis performed with four different pairs of
primers reveals complete lack of PNPLA2 RNA in patient sample. From upper image: first pair of primers encompassing exons 1 and
2 (217 nt); second pair encompassing exons 2 and 3 (539 nt); third pair encompassing exons 3, 4, 5, 6 and 7 (645 nt); fourth pair
encompassing exons 7, 8, 9 and 10 (645 nt). GAPDH has been used as control for RNA normalization (512 nt). M: marker; C: control;
P: patient.
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years old), with mild evolution, and a dramatic hearth
failure that caused patient death at the age of 59.20 Finally,another paper by our group described an Italian family in
which NLSDM was diagnosed in three members. Two
brothers had late onset myopathy, while their sister did not
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betes.17 In these cases, as well as in our present patients,
the manifestation of clinical symptoms with variable de-
gree of severity might be associated both with gender of
patients and lifestyle. Indeed, it has been reported that in
pre-menopausal women endogenous estrogens play a pro-
tective role against cardiovascular disorders. These hor-
mones regulate lipid metabolism, in particular in liver and
adipose tissue but they can exert an effect also in other
tissues.26 Moreover, estrogens prevent lipid accumulation
and inflammation in skeletal muscle.27 Finally, the estro-
gens participate to regulation of expression of peroxisome
proliferator activated receptors (PPARs), a group of re-
ceptors involved in fatty acids and glucose utilization in
skeletal and cardiac cells.28 The effect of diet and exercise
on number and size of skeletal muscle LDs29 has also been
investigated. Caloric restriction, as well as acute exercise,
decrease lipid accumulation in muscle cells, while long-
term exercises act on improving insulin sensitivity and
then alter LD morphology, cytoplasmic localization and
their interaction with mitochondria. Additional clinical
studies are required to clarify whether ATGL mutations
combined with different lifestyle or gender can play a key
role in development of various NLSDM phenotype.
In conclusion, a novel pathogenic mutation of PNPLA2
gene has been identified in two siblings affected by NLSDM.
This mutation completely abolishes gene expression and
determines early onset of muscle weakness which evolves
in slowly progressive myopathy. These data expand the
spectrum of PNPLA2 mutations onset and provide further
evidence of phenotypic heterogeneity in NLSDM.
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tations and human disease.HumGenet. 2017;136(9):1093e1111.
24. Xu C, Zhao Y, Liu J, et al. Muscle MRI in neutral lipid storage
disease with myopathy carrying mutationc 187þ1G>A. Musc
Nerve. 2015;51(6):922e927.
25. Riordan JD, Nadeau JH. Modifier genes, Network resilience, and
the genetics of health. Am J Hum Genet. 2017;101(2):177e191.
26. Palmisano BT, Zhu L, Eckel RH, et al. Sex differences in lipid
and lipoprotein metabolism. Mol Metab. 2018;15:45e55.
27. Mauvais-Jarvis M, Clegg DJ, Hevener AL. The role of estrogens
in control of energy balance and glucose homeostasis. Endocr
Rev. 2013;34(3):309e338.
28. Aseer KJ, Kim SW, Lee DG, et al. Gender-dimorphic regulation
of muscular proteins in response to high fat diet and sex steroid
hormones. Biotechnol Bioproc Eng. 2014;19:811e828.
29. Daemen S, van Polanen N, Hesselink KC. The effect of diet and
exercise on lipid droplet dynamics in human muscle tissue. J
Exp Biol. 2018;221(Pt Suppl 1),jeb167015.
